How will the findings from the study of adjuvant capecitabine in TNBC presented at SABCS 2018 (CIBOMA/2004-01_GEICAM/2003-11) affect standard of care?
Answer from: Medical Oncologist at Academic Institution
In order to decide how this influences practice, it is important to contrast some of the differences between this trial, CREATE-X and other studies with capecitabine in the adjuvant setting.In the GEICAM/2003-11_CIBOMA/2004-01 trial, 876 patients with triple negative breast cancer (TNBC) were enroll...
Comments
Medical Oncologist at Christie NHS Foundation Trust In GEICAM/CIBOMA the subset of women with non-basa...
Medical Oncologist at Medical College of Wisconsin I always wondered why additional chemotherapy(cape...
Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center Adjuvant Capecitabine for High risk TNBC patients ...
Medical Oncologist at Medical College of Wisconsin Also, I seem to encounter scenarios frequently whe...
Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center Different trials have slightly different eligibili...
In GEICAM/CIBOMA the subset of women with non-basa...
I always wondered why additional chemotherapy(cape...
Adjuvant Capecitabine for High risk TNBC patients ...
Also, I seem to encounter scenarios frequently whe...
Different trials have slightly different eligibili...